Canaccord Genuity maintains Buy rating on AngioDynamics, $20 price target
Canaccord Genuity kept a Buy rating on AngioDynamics with a $20 price target, suggesting a 78.1% upside. The company reported $80.9M revenue, up 6.9% YoY, and expects positive cash flow for the fiscal year.
How this was made
The 30-second read
Why it matters
The upgrade could attract new buying interest, supporting a price rally toward the target.
Market read
Analyst rating change provides a fresh catalyst for a small‑cap healthcare stock, offering a potential short‑term trade idea.
What to watch
Potential competitive pressure from larger vascular device makers and upcoming regulatory reviews.
Background
Canaccord Genuity's note reiterates a Buy stance and sets a $20 price target based on recent revenue and cash‑flow metrics.
Ticker impact
Canaccord Genuity maintained a Buy rating on AngioDynamics and raised its price target to $20, citing $80.9M revenue and positive cash‑flow outlook.
likely upward pressure as investors price in the $20 target and strong cash‑flow outlook
The new target implies a 78% upside from the recent close, providing a clear catalyst for buying.
Market effects
Positive signal for the med‑tech sector, especially companies focused on thrombectomy and vascular devices.
Limited to U.S. small‑cap healthcare investors.
Minor, as AngioDynamics is a niche player.
Counterpoint
The rating may be overly optimistic if revenue growth stalls or cash‑flow turns negative in later quarters.
Key entities
- companyAngioDynamics
Medical device maker specializing in vascular and thrombectomy technologies.
- analyst_firmCanaccord Genuity
Equity research firm providing the rating and target.
